14
ALL14
GenfitYear
14
ALL2
20253
20232
20224
20213
2020DEALS // DEV.
14
ALL7
Deals7
DevelopmentsCountry
14
ALL11
FRANCE1
SWITZERLAND2
U.S.A14
ALL1
Celloram1
Genoscience Pharma2
HealthCare Royalty2
Ipsen6
Not Applicable1
Seal Rock Therapeutics1
VersantisTherapeutic Area
14
ALL12
Hepatology (Liver, Pancreatic, Gall Bladder)2
OncologyStudy Phase
14
ALL6
Phase III3
Phase II1
Phase I/ Phase II3
Phase I1
PreclinicalDeal Type
7
ALL2
Acquisition2
Financing3
Licensing AgreementProduct Type
14
ALL2
Other Small Molecule12
Small moleculeDosage Form
12
ALL1
Dosage Strength/Form1
Infusion2
Intraperitoneal Injection1
Suspension6
Tablet1
Tablet, Film CoatedLead Product
14
ALL1
CLM-0226
Elafibranor2
Ezurpimtrostat1
Nitazoxanide1
SRT-0153
VS-01Target
10
ALL1
Ammonia clearance5
PPAR gamma2
PPT11
Pyruvate synthase1
UndisclosedLead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Genfit Completes Royalty Financing with HCRx & Repurchase Offer Results
Details : The financing aims to advance the company's product pipeline including VS-01, an investigational drug based on a proprietary scavenging liposomal technology. It is treated in patients with ACLF.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $141.2 million
March 20, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $201.7 million
Deal Type : Financing
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
GENFIT Announces Royalty Financing, Debt Overhang Resolution Plan
Details : The company will use the proceeds to develop its pipeline focused on Acute-on-Chronic Liver Failure (ACLF), including VS-01, a first-in-class innovative liposomal-based therapeutic product.
Product Name : VS-01
Product Type : Other Small Molecule
Upfront Cash : $133.2 million
January 30, 2025
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : HealthCare Royalty
Deal Size : $189.5 million
Deal Type : Financing
Lead Product(s) : CLM-022
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Recipient : Celloram
Deal Size : $175.5 million
Deal Type : Licensing Agreement
Details : Under the agreement, GENFIT will advance Celloram’s first-in-class inflammasome inhibitor, CLM-022, a triterpenoid derivative that targets the inflammasome machinery, in liver disease indications.
Product Name : CLM-022
Product Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : CLM-022
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Recipient : Celloram
Deal Size : $175.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Recipient : Ipsen
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GFT505 (elafibranor) is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease.
Product Name : GFT505
Product Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2023
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Recipient : Ipsen
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Seal Rock Therapeutics
Deal Size : $106.8 million
Deal Type : Licensing Agreement
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
Details : Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.
Product Name : SRT-015
Product Type : Small molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Seal Rock Therapeutics
Deal Size : $106.8 million
Deal Type : Licensing Agreement
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Versantis
Deal Size : $107.6 million
Deal Type : Acquisition
Details : VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.
Product Name : VS-01
Product Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : VS-01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Versantis
Deal Size : $107.6 million
Deal Type : Acquisition
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Details : GNS561 (ezurpimtrostat) is a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor that blocks autophagy. Autophagy is activated in tumor cells in response to certain conditions, due to a tumor cell growth in advanced cancers.
Product Name : GNS561
Product Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Ipsen
Deal Size : $583.0 million
Deal Type : Licensing Agreement
Details : The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT’s GFT505, an investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC).
Product Name : GFT505
Product Type : Small molecule
Upfront Cash : $137.7 million
December 17, 2021
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Ipsen
Deal Size : $583.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Genoscience Pharma
Deal Size : $3.4 million
Deal Type : Acquisition
On heels of Global Strategic Partnership Announced Today, GENFIT Acquires Rights to Novel Asset
Details : Through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland.
Product Name : GNS561
Product Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Ezurpimtrostat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Genoscience Pharma
Deal Size : $3.4 million
Deal Type : Acquisition
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company presents Elafibranor, dual agonism of peroxisome proliferator-activated alpha/delta receptors found to be efficacious in the treatment of PBC, a rare liver disease.
Product Name : GFT505
Product Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2021
Lead Product(s) : Elafibranor
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable